Transcription factor NRF2 in lung cancer

Description of the granted funding

Lung cancer is one of the most common and aggressive cancer types worldwide with a dismal 5-year survival rate of ca. 15%. The vast majority of these are non-small cell lung cancers which are genetically and morphologically very diverse, and therefore novel insights into oncogenic mechanisms are urgently needed. Redox-activated transcription factor NRF2 that regulates pro-survival genes has been shown to be commonly dysregulated in lung cancer. This project aims at elucidating the mechamisms of dysregulation of NRF2 and associated factors, its role in cancer cell-microenvironment interactions and the use of NRF2 status as a predictive biomarker for treatment efficacy and prognosis. The proposed studies will broaden our understanding of the role of NRF2 in lung cancer that has a potential to yield significant findings affecting its prevention, diagnostics and treatment.
Show more

Starting year

2020

End year

2022

Granted funding

Anna-Liisa Levonen Orcid -palvelun logo
250 000 €

Funder

Research Council of Finland

Funding instrument

Academy projects

Other information

Funding decision number

332697

Fields of science

Biomedicine

Research fields

Biolääketieteet

Identified topics

cancer